Dr. Sznol Discusses the Importance of Clinical Trials in RCC

Video

In Partnership With:

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma.

Mario Sznol, MD, professor of Medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the importance of clinical trials in renal cell carcinoma (RCC).

Immunotherapy has begun to show promise in the treatment of patients with RCC. In April 2018, the FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a frontline treatment for intermediate- and poor-risk patients with advanced RCC based on findings from the CheckMate-214 trial.

Sznol says that the message he would like to get across to the community oncologist is that they should consider their patients with RCC for clinical trials of immunotherapy, as it is not yet fully understood how to use these agents optimally. For most patients, Sznol says that a combination of 2 immunotherapy agents, or an immunotherapy agent with a VEGF inhibitor will be an effective therapy in the frontline setting. Sznol says that if clinical trials with immunotherapy agents are not done is RCC, then the current landscape will remain confusing for oncologists.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD